"Metformin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
Descriptor ID |
D008687
|
MeSH Number(s) |
D02.078.370.141.450
|
Concept/Terms |
Metformin- Metformin
- Dimethylbiguanidine
- Dimethylguanylguanidine
|
Below are MeSH descriptors whose meaning is more general than "Metformin".
Below are MeSH descriptors whose meaning is more specific than "Metformin".
This graph shows the total number of publications written about "Metformin" by people in this website by year, and whether "Metformin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2002 | 1 | 1 | 2 |
2005 | 1 | 2 | 3 |
2008 | 1 | 1 | 2 |
2009 | 3 | 2 | 5 |
2010 | 8 | 3 | 11 |
2011 | 7 | 5 | 12 |
2012 | 9 | 7 | 16 |
2013 | 5 | 0 | 5 |
2014 | 14 | 2 | 16 |
2015 | 5 | 4 | 9 |
2016 | 7 | 5 | 12 |
2017 | 2 | 3 | 5 |
2018 | 7 | 4 | 11 |
2019 | 9 | 3 | 12 |
2020 | 12 | 4 | 16 |
2021 | 7 | 4 | 11 |
2022 | 5 | 1 | 6 |
2023 | 9 | 0 | 9 |
2024 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Metformin" by people in Profiles.
-
Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies. Cancer Res Commun. 2024 02 12; 4(2):378-387.
-
Metformin in Conjunction With Stereotactic Radiotherapy for Early-stage Non-small Cell Lung Cancer: Long-term Results of a Prospective Phase II Clinical Trial. Anticancer Res. 2024 Jan; 44(1):133-137.
-
The Effectiveness of Metformin in Managing Second Generation Antipsychotic-Induced Weight Gain in Children and Adolescents. J Clin Psychiatry. 2023 Dec 20; 85(1).
-
Editorial: Global excellence in natural products for endocrine disorders. Front Endocrinol (Lausanne). 2023; 14:1325355.
-
More on the Magic of Metformin. Cardiology. 2023; 148(6):545-546.
-
Metformin Disrupts Signaling and Metabolism in Fetal Hepatocytes. Diabetes. 2023 09 01; 72(9):1214-1227.
-
Proteogenomic insights suggest druggable pathways in endometrial carcinoma. Cancer Cell. 2023 09 11; 41(9):1586-1605.e15.
-
Phase I / II trial of metformin as a chemo-radiosensitizer in a head and neck cancer patient population. Oral Oncol. 2023 10; 145:106536.
-
Baseline leptin predicts response to metformin in adolescents with type 1 diabetes and increased body mass index. Diabetes Obes Metab. 2023 11; 25(11):3420-3423.
-
Utilization and Predictors of Adjuvant Metformin for Children and Adolescents on Mixed Receptor Antagonists (Second-Generation Antipsychotics). J Am Acad Child Adolesc Psychiatry. 2023 11; 62(11):1245-1255.